Edition:
United States

Profile: Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

334.20DKK
10:59am EDT
Change (% chg)

kr.-3.15 (-0.93%)
Prev Close
kr.337.35
Open
kr.339.20
Day's High
kr.339.30
Day's Low
kr.333.40
Volume
1,941,842
Avg. Vol
2,482,111
52-wk High
kr.349.70
52-wk Low
kr.265.15

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Address

Novo Nordisk A/S

Novo Alle
BAGSVAERD     2880
P: +4544.448888
F: +4544.436633

Company Web Links